Windtree Therapeutics

Company Overview

August 26, 2022

WINDTREE THERAPEUTICS™

(NASDAQ: WINT)

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development activities, or otherwise as to future events. The forward-looking statements provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “will,” “should,” “could,” “targets,” “projects,” “contemplates,” “predicts,” “potential” or “continues” or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. These risks and uncertainties are further described in the Company's periodic filings with the Securities and Exchange Commission (“SEC”), including the most recent reports on Form 10-K, Form 10-Q and Form 8-K, and any amendments thereto (“Company Filings”). Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Under no circumstances shall this presentation be construed as an offer to sell or as a solicitation of an offer to buy any of the Company's securities. In addition, the information presented in this deck is qualified in its entirety by the Company Filings. The reader should refer to the Company Filings for a fuller discussion of the matters presented here.

Windtree Therapeutics and Istaroxime Highlights

- **Biopharmaceutical company with advanced clinical focused on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations** (NASDAQ: WINT)

- **Through three Phase 2 global studies, lead asset istaroxime has consistently demonstrated a highly unique and attractive profile**
  - It is the only acute heart failure or shock drug that has demonstrated both significant improvement in cardiac function of a failing heart, as well as rapid and significant improvement in blood pressure, with what so far has been a differentiating safety profile (avoiding many of the use-limiting side effects of existing therapies)

- **Recent positive Phase 2 study with istaroxime in early cardiogenic shock (ECS) paves the way for what we believe is a relatively fast and less expensive developmental and regulatory pathway**
  - Precedent shows blood pressure response can be acceptable as the primary endpoint in a pivotal shock study. Additionally, istaroxime demonstrated significant other benefits that we expect will continue to help us build a strong evidence-based position in the larger Phase 3 planned for 2023.
  - Given what we believe to be an attractive opportunity that may be pursued with less spend and have faster time to market, Cardiogenic shock has become the organization's priority and focus

- **Highly experienced management team and company leadership**

Pipeline

Lead Products	Indication	Phase	Development Status	Regulatory Status
Istaroxime	Acute Heart Failure	Phase 2b	• Plan a second Phase 2b clinical trial in ~300 patients targeted to start once clinical trial operations are fully funded	*FDA Fast Track Designation*
Istaroxime	Early Cardiogenic Shock	Phase 2	• Positive Phase 2 study • Planning the execution of the next studies and plans to meet with regulatory agencies regarding development path	*Potential for Breakthrough Designation*
Oral SERCA2a Activators	Chronic HF; potentially HFpEF	Preclinical	• Chronic and Acute Heart Failure • Target for collaboration/partnership	*Preclinical*
Rostafuroxin	Genetically Associated HTN	Phase 2b	• Out-licensing opportunity	
KL4 Surfactant – COVID 19	COVID 19 Pilot; Possible invasive Tx for RDS in neonates	Phase 2	• Study completed; Results presented March 2022 • Global out-license to Lee's Pharmaceuticals	*FDA, EMA Orphan Drug for RDS*
AEROSURF / Aerosolized KL4	KL4 surfactant Drug/Device Tx for RDS	Phase 2b	• Global out-license to Lee's Pharmaceuticals	*FDA Fast Track Designation, Orphan Drug*

Strategy for Value Creation



Represents topline data available

*study initiation pending positive data, regulatory input and adequate funding
**study initiation pending adequate funding

Istaroxime

Early Cardiogenic Shock

Additional potential indication in active clinical development

WINDTREE THERAPEUTICS™

Cardiogenic Shock

A severe presentation of heart failure characterized by **very low blood pressure and hypoperfusion** accompanied by high filling pressures of the heart and decreased urine output. It is a **treatment emergency**

- Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperfusion and hypoxemia
- Commonly requires pharmacological or mechanical intervention to increase SBP to >90mmHg and improve tissue perfusion
- High in-hospital mortality (~30-40%) and substantial morbidity in survivors[1]
- Represents an approximate $1.25B total market potential[2]

WINDTREE THERAPEUTICS™

1) Kolte D, American Heart Association; 2014 Jan 13
2) Estimates from claims data and epi data September 2021, multiplied by assumed various regional prices

Early Cardiogenic Shock Treatment

Istaroxime Potential Opportunity to Address Significant Unmet Need

- No satisfactory pharmacological intervention to reverse the conditions
  - Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and even increases in mortality that limit their usefulness and position them as “rescue medicines” for severe cases
- A therapy that can be used **earlier** to rapidly **improve blood pressure and cardiac function without unwanted side effects** is needed

100 U.S. Cardiologists *questioned on degree of* ***unmet need for new innovative pharmacologic treatments for ECS***



✓ **84%** of the cardiologists responded they would be **likely to extremely likely to use** istaroxime for early cardiogenic shock patients

✓ Majority responded they would position utilization before use of other existing classes of therapies such as inotropes and vasopressors

WINDTREE THERAPEUTICS™

Market research conducted by Sermo, a leading provider of real time physician insights

Istaroxime – Novel First-in-Class Therapy

Novel intravenous agent designed to **improve systolic contraction *and* diastolic relaxation of the heart**

Dual Mechanism of Action

1 **Inhibition of the sodium-potassium pump and effects on the sodium-calcium exchanger results in increased contraction**

Istaroxime

2 **Stimulation of SERCA2a activity enhances calcium reuptake resulting in improvement of the diastolic relaxation (greater fill volume) and subsequent contraction cycle**

Impact on both systolic and diastolic dysfunction



WINDTREE THERAPEUTICS™

Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials

E/e' (cardiac filling pressure)

Istaroxime 1.0 µg/kg/min vs. placebo



Stroke Volume



Improved cardiac function ***and*** SBP along with a favorable renal and tolerance profile

Systolic Blood Pressure (SBP)

Istaroxime 1.0 µg/kg/min vs. placebo



GFR (Renal Function)



WINDTREE THERAPEUTICS™

Early Cardiogenic Shock Treatment
Istaroxime Potential Opportunity for Accelerated Pathway

Potential for a relatively fast and less expensive developmental and regulatory pathway

FDA Regulatory Commentary with Break-Through Therapy Designation Potential

Sponsors are potentially **not required to show benefit other than an increase in blood pressure to support approval of drugs to treat hypotension in the setting of shock**(1)

Precedent NDA: Giapreza® (IV Angiotensin II), approved in 2017 for increasing MAP in distributive shock – a different type of shock, not a competitor to istaroxime in early cardiogenic shock)(2) Precedent also indicates potential accelerated regulatory pathway and review opportunities

WINDTREE THERAPEUTICS™

1) Kosaraju A, Hai O. Cardiogenic Shock. [Updated 2019 Jan 25]. In: www.ncbi.nlm.nih.gov/books/NBK482255/ CSRC Think Tank - July 24, 2019
2) Senatore et al., Am J Cardiovasc Drugs, February 2019, Volume 19, Issue 1, pp 11–20 (https://doi.org/10.1007/s40256-018-0297-9)

SEISMiC Early Cardiogenic Shock Study

Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure

60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF

Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime. Two istaroxime target doses were evaluated, 1.5µg/kg/min in the first group and 1.0 µg/kg/min in the next group.

Primary endpoint was SBP AUC at 6 hours comparing istaroxime to placebo

Secondary measures included: SBP profile at 24 hours, echocardiology measures associated systolic and diastolic cardiac function, renal function, various safety and tolerability measures

WINDTREE THERAPEUTICS™

Difference in SBP Profile



Systolic BP Improvements Persisted over 24 Hours



Cardiac Function Improvement

Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including:

- **Cardiac index significantly increased**
- **Stroke volume index substantially increased** ($4\ mL/m^2$) approaching statistical significance
- Other echocardiographic measurements improved:
  - **Left atrial area was reduced**
  - **Left ventricular end systolic volume was reduced**
  - **Left ventricular end diastolic volume was reduced**



WINDTREE THERAPEUTICS™

Treatment was Associated with a Favorable Renal Profile

Renal function was not decreased in istaroxime treated patients



Data shown as means and standard errors

1.0 µg/kg/min Produced a Favorable Effect on SBP

1.0 µg/kg/min dosing was associated with:

- Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function
- More favorable adverse event, serious adverse event and clinical event profile



WINDTREE THERAPEUTICS™

All Subjects (n=60)

SEISMiC Results Summary

SEISMiC was a positive study in early cardiogenic shock patients

- ✓ Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025)
  - SBP increases were rapid within the first hour and sustained through the 96-hour post-infusion measure
- ✓ Key secondary endpoints of systolic and diastolic cardiac function and performance were improved
- ✓ Renal function was maintained
- ✓ SEISMiC provided valuable information for optimizing our dose moving forward
- ✓ These data substantiate and advance the rationale for istaroxime as a potential treatment for cardiogenic shock and support the existing data from the program in AHF

WINDTREE THERAPEUTICS™

Relevance to the Acute Heart Failure (AHF) Program

- The early cardiogenic shock trial results are consistent with Windtree's Phase 2 AHF studies and complementary to further advancement in AHF.
- While SEISMiC was an early cardiogenic shock study, the patients studied had very severe AHF providing valuable insight into treating more severe AHF patients.
- As an acute cardiac treatment:

Istaroxime has the potential to effectively improve cardiac function without reducing SBP and/or renal function (common side effects of currently available rescue agents)

Cardiogenic Shock Development Strategy



** Study plans and progression to Phase 3 dependent upon regulatory alignment and resourcing*

WINDTREE THERAPEUTICS™

Plan for Dose Optimization – Extension Study

Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure

Study objectives:

- ✓ Advance the characterization of the physiology associated with longer istaroxime dosing as well as evaluate a dose titration
- ✓ More fully illuminate the effects and potential benefits associated with SERCA2a activation
- ✓ Support our regulatory strategy for istaroxime

Current study plan design:

Double-blind, placebo controlled in up to 30 patients (2:1 randomization) with SBP between 70-100mmHg conducted in sites in the US, EU and LATAM

Two treatment arms of 60-hour infusions, titrating down from 1.0 starting dose
Placebo controlled arm

Multiple physiologic measures associated with cardiac function,
blood pressure and safety
Approximately 6 months of recruitment

** Study plans and progression dependent upon regulatory alignment and resourcing*

Istaroxime

Dual Mechanism
SERCA2a Activator

Acute Heart Failure



WINDTREE THERAPEUTICS™

Heart Failure – Large, Growing Market But Underserved

The prevalence and mortality of heart failure is high and increasing

#1 cause of U.S. hospitalization in patients > 65 years old

Annual Admissions

~1.3M U.S.

~1.5M E.U.

Patients

7M U.S.,

25M+ worldwide

~7%

In-patient mortality

30-day mortality can exceed 10%

>$18B

annual U.S. hospital costs

Most expensive of the Medicare diagnoses

0

New pharmacologic advancements in acute heart failure for decades

Lack of therapeutic advances led the FDA to issue new Heart Failure Guidance in July 2019 for greater development flexibility in acceptable endpoints, specifically acknowledging mortality is not required

WINDTREE THERAPEUTICS™

Sources: American Heart Association; DRG Data

Acute Heart Failure – Significant Unmet Clinical Need

Patient Management Goals

- **Clinical objectives** for AHF patient management include:
  - **Relieve pulmonary congestion** and general edema (e.g., “dry out”) with IV diuretics
  - **Improve cardiac function** and peripheral/organ perfusion
  - **Achieve stable, fully compensated** clinical state
  - Transition to oral, outpatient medicines (for chronic management of heart failure)

Current Treatment Options

- **Current approaches to acutely improve cardiac function are associated with unwanted effects**:
  - Heart rhythm disturbances
  - Increased heart rate and myocardial oxygen demand
  - Decreased blood pressure
  - Potential damage to the heart muscle
  - Worsening renal function
  - Mortality
- **Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients who are also generally resistant to diuretic therapy and often discharged in a sub-optimal state**

WINDTREE THERAPEUTICS™

1) ADHERE Registry, n=48,567; JAMA 2006
2) European Journal of Heart Failure; Voors, PRE-RELAX AHF Study; 2011; 13

Istaroxime AHF Phase 2a & 2b Studies

Phase 2a

n=**120**
ADHF Patients

Dosing=
0.5, 1, 1.5 µg/kg/min

6 hour
Infusion

- Primary: PCWP significantly improved
- Stroke Vol & SBP – significant increase
- Heart Rate (HR) - lowered

Phase 2b

n=**120**
ADHF Patients
(dyspnea plus need
for IV furosemide ≥ 40mg)

Dosing=
0.5, 1.0 µg/kg/min

24 hour
Infusion

Results

Positive Phase 2 trial results demonstrated improved cardiac function **without unwanted side effects of existing rescue therapies**

WINDTREE THERAPEUTICS™

Primary Endpoint Achieved
Significant Changes in E/e' Ratio[1] and Stroke Volume

Istaroxime 0.5 µg/kg/min vs. placebo



E/e'

Istaroxime 1.0 µg/kg/min vs. placebo





Stroke Volume



WINDTREE THERAPEUTICS™

1) E/e' echocardiographic assessment of PCWP; Note: Data shown as means and standard errors

Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

Istaroxime 0.5 µg/kg/min vs. placebo



Systolic Blood Pressure (SBP)

Istaroxime 1.0 µg/kg/min vs. placebo





GFR (Renal Function)



WINDTREE THERAPEUTICS™

Data shown as means and standard errors

Heart Rate Decreased and No Increases in Cardiac Troponins

Istaroxime 0.5 µg/kg/min vs. placebo



Heart Rate

Istaroxime 1.0 µg/kg/min vs. placebo



cTnT – 0 to 24 hours



Cardiac TnT (Myocardial Damage)

cTnT – 24 to 72 hours



WINDTREE THERAPEUTICS™

Favorable Profile Observed with 24-hour Holter Monitoring

Clinically Significant Arrhythmias





Ventricular Tachycardia





WINDTREE THERAPEUTICS™

PVCs (n°/24 hours) shown as median, ventricular tachycardia and clinically significant arrhythmias shown as percentage of patients

Istaroxime – Acute Heart Failure

Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position

Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally*

Enrich therapeutic impact by leveraging characteristics in target population whose needs match the unique attributes of istaroxime: patients with low blood pressure and/or diuretic resistance

Increase infusion time to >24 hours in pursuit of dose optimization

Primary endpoint will again be E/e', but also obtain data on measures that will inform Phase 3 design and pivotal endpoint

Pending adequate funding; ~18 months to execute

WINDTREE THERAPEUTICS™

* Estimates

Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform

The Company also has pre-clinical programs on product candidates including:

Selective SERCA2a Activators

- **Oral & i.v.** therapies for chronic heart failure (CHF) and AHF
- Attractive approach for **heart failure with preserved ejection fraction (HFpEF)**

Dual Mechanism, (SERCA2a & Na+/K+) Compounds

"Next generation istaroxime" as oral/i.v. for **in-patient acute and out-patient chronic use**

These next generation agents help form complete chronic and acute heart failure treatment portfolio for both licensing/partnership and potential commercialization

Dual Mechanism, (SERCA2a & Na+/K+) Compounds
"Next generation istaroxime" as oral/i.v. for in-patient acute and out-patient chronic use

Summary

- Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient
  - The data is consistent, across all regions/populations and across many endpoints (including many in early cardiogenic shock despite small trial)
- Istaroxime has demonstrated a highly unique and desirable profile as compared to existing therapies:
  - Improved cardiac function **and** SBP while maintaining renal function and overall safety profile
- Recent positive Phase 2 study with istaroxime in early cardiogenic shock (ECS) paves the way for what we believe is a relatively fast and less expensive developmental and regulatory pathway
- The AHF program will proceed with business development (which remains a pre-Phase 3 strategy for istaroxime) and/or additional resourcing while also advancing the next generation, oral SERCA2a activators for chronic and acute HF including HFpEF

WINDTREE THERAPEUTICS™

Financial Summary & Capitalization

Cash & Equivalents of ~$11.4 million as of June 30, 2022

Securities	Common Equivalents as of August 11, 2022
Common Stock	30,627,878
Options (WAEP $7.84)	4,046,604
Restricted Stock Units	560,900
Warrants (WAEP $6.64)	16,546,336
Fully Diluted Equivalents	51,781,718

WINDTREE THERAPEUTICS™

Strategy for Value Generation



www.windtreetx.com

WINDTREE THERAPEUTICS™

WINDTREE
THERAPEUTICS™

Appendix

WINDTREE THERAPEUTICS™

Istaroxime Unique Opportunity With Attractive Risk / Return Profile

1. Highly consistent results across 3 controlled Phase 2 studies (and 300 patients dosed thus far), in a spectrum of severity and executed in all regions of the world

2. Attractive profile as the only acute heart failure or shock drug that has been shown to significantly improve cardiac function of a failing heart, while rapidly and significantly improving blood pressure, with what so far has been a differentiating safety profile (avoiding many of the use-limiting side effects of existing therapies such renal, arrhythmias, etc.)

3. Complementary acute CV programs with high unmet need and no active or developing competition

Istaroxime: Attractive Risk, Time, Cost and Return Profile

5. Long, successful history of CMC

4. Faster and less expensive developmental and regulatory pathway possible
   - Attractive pivotal endpoint of blood pressure response is expected to be more straight-forward and better align with a smaller study than one requiring clinical outcome measures.
   - Additionally, istaroxime demonstrated significance in many other benefits that we expect will continue to help us build a strong evidence-based position with dose-optimization and the larger Phase 3 planned for 2023.

WINDTREE THERAPEUTICS™

Istaroxime Phase 2a (HORIZON-HF) Study

- Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU
- Hospitalized with AHF, with criteria including:
  - LVEF ≤ 35%
  - SBP 90-150 mmHg
- N=120 (30/group)
- Significant improvement in PCWP, SBP, heart rate was lower. Istaroxime was generally well tolerated with no unexpected adverse events

Primary Endpoint:
PCWP Significant Improvements



Dose-dependent Increase in SBP



WINDTREE THERAPEUTICS™

Istaroxime AHF Phase 2b Adverse Events

Event	Pooled placebo (n=39)	Istaroxime 0.5 mg/Kg/min (n=41)	Istaroxime 1.0 mg/Kg/min (n=40)
All adverse events	23 (59.0%)	31 (75.6%)	33 (82.5%)
Adverse events leading to discontinuation	1 (2.6%)	-	4 (10.0%)
Serious adverse events	2 (5.1%)	2 (4.9%)	6 (15.0%)
Cardiac death	-	-	1 (2.5%)
Cardiogenic shock	-	-	1 (2.5%)*
Cardiac failure	1 (2.6%)	2 (4.9%)	3 (7.5%)
Renal embolism	-	-	1 (2.5%)
Transient ischemic attack	1 (2.6%)	-	-
Hyperventilation	1 (2.6%)	-	-
Hypotension	1 (2.6%)	-	-
Adverse Drug Reactions†	10 (25.6%)	23 (56.1%)	25 (62.5%)
Cardiovascular††	**9 (23.1%)**	**4 (9.8%)**	**7 (17.5%)**
Gastrointestinal‡	2 (5.1%)	4 (9.8%)	14 (35.0%)
Infusion site pain/inflammation	-	20 (48.8%)	13 (32.5%)

Note: data shown as n° patients (%) - patients can have more than one event during the 30-day follow up period
* Same patient who then died, and 1 additional death occurred at Day 31 (cardiac death) outside the 30 day window
† Adverse Drug Reactions are AEs related to study drug
††Most common - arrhythmia, atrial fibrillation, cardiac failure, ventricular tachycardia
‡ Most common - abdominal pain, nausea, vomiting, diarrhoea

WINDTREE THERAPEUTICS™

SEISMiC: Serious Adverse Events and Adverse Drug Reactions

Event	Istaroxime (N=29)	Placebo (N=31)
All adverse events	27 (93%)	25 (81%)
Serious adverse events	6 (21%)	6 (19%)
Cardiac arrest	1 (3%)	0
Cardiac failure	2 (7%)	2 (6%)
Cardiac failure acute	0	1 (3%)
Cardiac ventricular thrombosis	0	1 (3%)
Cardiac artery stenosis	0	1 (3%)
Ventricular fibrillation	1 (3%)	0
Ventricular tachycardia	1 (3%)	0
Coronavirus infection	0	1 (3%)
Pneumonia	1 (3%)	0
Acute kidney injury	1 (3%)	0
Adverse drug reactions†	15 (52%)	3 (10%)
Gastrointestinal‡	9 (31%)	2 (6%)
Infusion site pain/inflammation	4 (14%)	1 (3%)

WINDTREE THERAPEUTICS™

Note: data shown as n (%); patients can have more than one event during the 30-day follow up period
† Adverse drug reactions are AEs possibly related or related to study drug
‡ Most common - nausea, vomiting

SEISMiC: Safety and Efficacy Appeared More Favorable with the 1.0 vs 1.5 µg/kg/min and Placebo

1.0 µg/kg/min dosing was associated with:

- **Early SBP increase and improvement in more echocardiographic parameters of cardiac function**
- **More favorable adverse event, serious adverse event and clinical event profile**

Clinical Events by Dose	Statistic	Placebo (N=31)	Istaroxime 1.0 µg/kg/min (N=16)	Istaroxime 1.5 µg/kg/min (N=13)
SBP AUC 0-24hrs	LS-Means (SE)*	209.9 (27.38)	282.7 (35.79)	304.1 (44.11)
Worsening HF through 96-hours	No. events	1 (3%)	0 (0%)	5 (38%)
Heart Failure Readmissions through 30-days	No. events	3 (12.9%)	0 (0%)	0 (0%)
Length in ICCU/CCU, days [c]	Mean (SD)	4.55 (2.23)	3.50 (1.41)	6.38 (4.46)
All-Cause Mortality through 30-Days	No. events (%)	1 (3%)	1 (6%)	3 (23%)
All-Cause mortality or HF readmission through 30-days	No. events (%)	4 (12%)	1 (6%)	3 (23%)

WINDTREE THERAPEUTICS™

* LS-Means and associated p-values from ANCOVA model adjusted for pooled site, treatment, and baseline systolic BP.

Acute Heart Failure

Significant Healthcare Issue with Significant Unmet Clinical Need

- Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state.
  - Low SBP in-patient mortality approximately two-fold greater than normal/high SBP[1]
  - There is a direct relationship between early drop in SBP and worsening renal function in acute heart failure2

In-Hospital Mortality Rates by Admission Systolic Blood Pressure Deciles (n = 48,567)



Gheorghiade, M. et al. JAMA 2006;296:2217-2226.

Early drop in systolic blood pressure and worsening renal function in Acute Heart Failure: renal results of Pre-RELAX-AHF Study



Voors, A. et al. European Journal of Heart Failure 2011; 13; 961-967

WINDTREE THERAPEUTICS™

1) ADHERE Registry, n=48,567; JAMA 2006
2) European Journal of Heart Failure; Voors, PRE-RELAX AHF Study; 2011; 13